Genedrive
Point-of-care molecular diagnostics for pharmacogenetic testing.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | £2.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| GBP | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (20 %) | (50 %) | (47 %) | (35 %) | (93 %) | 12 % | 811 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (50 %) | (200 %) | (539 %) | (762 %) | (10949 %) | (8982 %) | (1118 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (125 %) | (150 %) | (1834 %) | (101 %) | (9541 %) | (9364 %) | (1412 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 441 % | 656 % | 7900 % | 7135 % | 833 % |
Source: Company filings or news article
Related Content
Genedrive PLC is a UK-based molecular diagnostics company specializing in developing and commercializing a point-of-need pharmacogenetic testing platform. The company was initially founded as Epistem Holdings Plc in 2007, floating on the London AIM market, and rebranded to Genedrive plc in July 2016 to reflect its new focus on molecular diagnostics. This strategic shift included divesting its legacy contract research services in 2018.
The company's core business revolves around a 'razor blade' model: placing its patented Genedrive® PCR platform in healthcare settings and generating revenue from the sale of single-use, temperature-stable test cartridges. This approach targets time-critical emergency care, enabling clinicians to make rapid decisions on medication and dosage based on a patient's genetic profile. The technology provides results in as little as 26 minutes, a significant speed advantage over traditional laboratory systems.
Genedrive's flagship products, developed in collaboration with NHS partners, include the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit. The MT-RNR1 kit is a first-of-its-kind test used in neonatal intensive care to prevent antibiotic-induced hearing loss by identifying a specific genetic variant. The CYP2C19 kit helps clinicians determine the appropriate antiplatelet therapy for stroke patients. Both products have been recommended by the UK's National Institute for Health and Care Excellence (NICE). The company also developed tests for HCV and COVID-19 and serves clients in North America, Europe, the Middle East, Africa, and the Asia Pacific region through distribution partners.
Keywords: pharmacogenetics, molecular diagnostics, point-of-care testing, genetic variants, PCR platform, genotyping, emergency medicine, antibiotic induced hearing loss, cardiovascular treatment, pathogen detection, in-vitro diagnostics, personalized medicine, medical diagnostic equipment, molecular medicine, nucleic acid amplification, NHS collaboration, NICE recommended, rapid diagnostics, clinical diagnostics, genetic screening